Point estimation for adaptive trial designs I: a methodological review
David S. Robertson, Babak Choodari-Oskooei, Munya Dimairo, Laura, Flight, Philip Pallmann, Thomas Jaki

TL;DR
This paper reviews methods to address bias in point estimation for adaptive clinical trial designs, emphasizing the importance of unbiased or bias-reduced estimators to improve estimate accuracy.
Contribution
It provides a comprehensive review of existing methods for bias reduction in adaptive trial estimations, classifies estimators, and discusses methodological gaps.
Findings
Classifies estimators into unbiased and bias-reduced categories
Highlights available software and implementation tools
Identifies gaps in current methodological approaches
Abstract
Recent FDA guidance on adaptive clinical trial designs defines bias as "a systematic tendency for the estimate of treatment effect to deviate from its true value", and states that it is desirable to obtain and report estimates of treatment effects that reduce or remove this bias. The conventional end-of-trial point estimates of the treatment effects are prone to bias in many adaptive designs, because they do not take into account the potential and realised trial adaptations. While much of the methodological developments on adaptive designs have tended to focus on control of type I error rates and power considerations, in contrast the question of biased estimation has received relatively less attention. This paper is the first in a two-part series that studies the issue of potential bias in point estimation for adaptive trials. Part I provides a comprehensive review of the methods to…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
